FUS

(redirected from FUS1)
Also found in: Encyclopedia.

FUS

A gene on chromosome 16p11.2 that encodes a multifunctional protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex, which is involved in pre-mRNA splicing and export of processed mRNA to the cytoplasm. FUS belongs to the FET family of RNA-binding proteins that regulate gene expression, maintain genomic integrity and process mRNA/microRNA processing.

Molecular pathology
FUS mutations cause amyotrophic lateral sclerosis type 6; a FUS/CHOP translocation (t(12;16)(q13;p11)) leads to the formation of a chimeric protein, which induces liposarcoma.

FUS

feline urological syndrome.
References in periodicals archive ?
The study, " Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center.
The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation for lung cancer patients in the U.
2004) found NP-based gene therapy to be effective in systemic gene treatment of lung cancer using a novel tumor suppressor gene, FUS1.
Anderson Cancer Center, the gene, FUS1, was found to be active in patients' metastatic non-small cell lung cancer tumors.
Intravenous nanoparticle formulation for delivery of FUS1 gene 263
p53 and FUS1 Tumor Suppressors Work Synergistically to Kill Cancer without Harming Normal Cells
Introgen will focus on oral formulations of its molecular therapeutics employing tumor suppressors such as p53, mda-7, and FUS1.
Introgen previously announced that it acquired the exclusive worldwide license for a family of at least 10 anti-cancer genes identified by the consortium including NRPL2 and FUS1.
3 family was determined to be TUSC2, also known as FUS1.
today provided an update of its ongoing clinical development of INGN 401, a nanoparticle formulation of the tumor suppressor gene FUS1.
The data from these studies demonstrate that intravenous administration of FUS1 significantly suppressed tumor growth, inhibited metastasis and prolonged survival in mice with metastatic lung cancer.
Research and development activities in the alliance will be conducted by Introgen and will focus on oral formulations of Introgen's molecular therapeutics employing tumor suppressors such as p53, mda-7, and FUS1.